|
Zofenoprilat
|
DB08766 |
|
|
N-(1-PHENYL-PROPYL)-FORMAMIDE
|
DB07436 |
|
|
2-(4-METHOXYPHENYL)ACETAMIDE
|
DB08767 |
|
|
N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
|
DB08768 |
|
|
1-((2-HYDROXYETHOXY)METHYL)-5-BENZYLPYRIMIDINE-2,4(1H,3H)-DIONE
|
DB07437 |
|
|
1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE
|
DB07439 |
|
|
YKP-1358
|
DB06109 |
[YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.] |
|
(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
|
DB08760 |
|
|
(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6'_4,5]thieno[3,2-f]quinolin-8-one
|
DB07430 |
|
|
(3S,6S)-3,6-bis(4-hydroxybenzyl)piperazine-2,5-dione
|
DB08761 |
|
|
AIT-034
|
DB06106 |
[AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do not respond to Neotrofin. AIT-034 does not induce the production of NGF, and its mechanism of action is therefore believed to be different than Neotrofin. There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia.] |
|
O-(((1R)-((N-PHENYLMETHOXYCARBONYL-L-ALANYL)AMINO)ETHYL)HYDROXYPHOSPHONO)-L-BENZYLACETIC ACID
|
DB08762 |
|
|
(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
|
DB07431 |
|
|
[N-(BENZYLOXYCARBONYL)AMINO](4-AMIDINOPHENYL)METHANE-PHOSPHONATE
|
DB08763 |
|
|
[[(3R,4R,5S,6R)-3-(butanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] N-phenylcarbamate
|
DB07432 |
|
|
VX-148
|
DB06103 |
[VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH). The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases.] |
|
(TERT-BUTYLOXYCARBONYL)-ALANYL-AMINO ETHYL-FORMAMIDE
|
DB07433 |
|
|
NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE
|
DB08732 |
|
|
METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE
|
DB07401 |
|
|
Azapropazone
|
DB07402 |
|
